Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer

Yaw Cheng Wang, Wen Wei Sung, Tzu Chin Wu, Lee Wang, Wen Pin Chien, Ya Wen Cheng, Chih Yi Chen, Shwn Huey Shieh, Huei Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

IL-10 is associated with tumor malignancy via immune escape. We hypothesized that IL-10 haplotypes categorized by IL-10 promoter polymorphisms at -1082A>G, -819C>T, and -592C>A might influence IL-10 expression and give rise to non-small cell lung cancer (NSCLC) patients with poor outcomes and relapse. We collected adjacent normal tissues from 385 NSCLC patients to determine IL-10 haplotypes by direct sequencing and polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Of the 385 tumors, 241 were available to evaluate IL-10 mRNA expression levels by real-time RT-PCR. The influence of IL-10 haplotypes on overall survival (OS) and relapse free survival (RFS) were determined by Kaplan-Meier and multivariate Cox regression analysis. The results showed that IL-10 mRNA levels were significantly higher in tumors with the non-ATA haplotype than with the ATA haplotype (P = 0.004). Patients with the non-ATA haplotype had shorter OS and RFS periods than did patients with the ATA haplotype. This may be associated with the observation that the number of tumor-infiltrating lymphocytes was decreased in the tumors with higher levels of IL-10. Consistently, T cells from the peripheral blood of the patients with non-ATA haplotype were more susceptible to apoptosis and less cytotoxic to tumor cells, compared to those from the patients with ATA haplotype. The results suggest that IL-10 can promote tumor malignancy via promoting T cell apoptosis and tumor cell survival, and IL-10 haplotype evaluated by PCR-RFLP or direct sequencing may be used to predict survival and relapse in resected NSCLC, helping clinicians to make appropriate decisions on treatment of the patients.

Original languageEnglish
Article numbere39525
JournalPLoS One
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 27 2012
Externally publishedYes

Fingerprint

relapse
lung neoplasms
interleukin-10
Non-Small Cell Lung Carcinoma
Interleukin-10
Haplotypes
haplotypes
Cells
Recurrence
Tumors
Survival
cells
Neoplasms
neoplasms
Polymorphism
T-cells
Polymerase chain reaction
Restriction Fragment Length Polymorphisms
restriction fragment length polymorphism
apoptosis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Wang, Y. C., Sung, W. W., Wu, T. C., Wang, L., Chien, W. P., Cheng, Y. W., ... Lee, H. (2012). Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One, 7(7), [e39525]. https://doi.org/10.1371/journal.pone.0039525

Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. / Wang, Yaw Cheng; Sung, Wen Wei; Wu, Tzu Chin; Wang, Lee; Chien, Wen Pin; Cheng, Ya Wen; Chen, Chih Yi; Shieh, Shwn Huey; Lee, Huei.

In: PLoS One, Vol. 7, No. 7, e39525, 27.07.2012.

Research output: Contribution to journalArticle

Wang, YC, Sung, WW, Wu, TC, Wang, L, Chien, WP, Cheng, YW, Chen, CY, Shieh, SH & Lee, H 2012, 'Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer', PLoS One, vol. 7, no. 7, e39525. https://doi.org/10.1371/journal.pone.0039525
Wang, Yaw Cheng ; Sung, Wen Wei ; Wu, Tzu Chin ; Wang, Lee ; Chien, Wen Pin ; Cheng, Ya Wen ; Chen, Chih Yi ; Shieh, Shwn Huey ; Lee, Huei. / Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. In: PLoS One. 2012 ; Vol. 7, No. 7.
@article{0595850fe27d45fca4c4ac8e49d3d746,
title = "Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer",
abstract = "IL-10 is associated with tumor malignancy via immune escape. We hypothesized that IL-10 haplotypes categorized by IL-10 promoter polymorphisms at -1082A>G, -819C>T, and -592C>A might influence IL-10 expression and give rise to non-small cell lung cancer (NSCLC) patients with poor outcomes and relapse. We collected adjacent normal tissues from 385 NSCLC patients to determine IL-10 haplotypes by direct sequencing and polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Of the 385 tumors, 241 were available to evaluate IL-10 mRNA expression levels by real-time RT-PCR. The influence of IL-10 haplotypes on overall survival (OS) and relapse free survival (RFS) were determined by Kaplan-Meier and multivariate Cox regression analysis. The results showed that IL-10 mRNA levels were significantly higher in tumors with the non-ATA haplotype than with the ATA haplotype (P = 0.004). Patients with the non-ATA haplotype had shorter OS and RFS periods than did patients with the ATA haplotype. This may be associated with the observation that the number of tumor-infiltrating lymphocytes was decreased in the tumors with higher levels of IL-10. Consistently, T cells from the peripheral blood of the patients with non-ATA haplotype were more susceptible to apoptosis and less cytotoxic to tumor cells, compared to those from the patients with ATA haplotype. The results suggest that IL-10 can promote tumor malignancy via promoting T cell apoptosis and tumor cell survival, and IL-10 haplotype evaluated by PCR-RFLP or direct sequencing may be used to predict survival and relapse in resected NSCLC, helping clinicians to make appropriate decisions on treatment of the patients.",
author = "Wang, {Yaw Cheng} and Sung, {Wen Wei} and Wu, {Tzu Chin} and Lee Wang and Chien, {Wen Pin} and Cheng, {Ya Wen} and Chen, {Chih Yi} and Shieh, {Shwn Huey} and Huei Lee",
year = "2012",
month = "7",
day = "27",
doi = "10.1371/journal.pone.0039525",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer

AU - Wang, Yaw Cheng

AU - Sung, Wen Wei

AU - Wu, Tzu Chin

AU - Wang, Lee

AU - Chien, Wen Pin

AU - Cheng, Ya Wen

AU - Chen, Chih Yi

AU - Shieh, Shwn Huey

AU - Lee, Huei

PY - 2012/7/27

Y1 - 2012/7/27

N2 - IL-10 is associated with tumor malignancy via immune escape. We hypothesized that IL-10 haplotypes categorized by IL-10 promoter polymorphisms at -1082A>G, -819C>T, and -592C>A might influence IL-10 expression and give rise to non-small cell lung cancer (NSCLC) patients with poor outcomes and relapse. We collected adjacent normal tissues from 385 NSCLC patients to determine IL-10 haplotypes by direct sequencing and polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Of the 385 tumors, 241 were available to evaluate IL-10 mRNA expression levels by real-time RT-PCR. The influence of IL-10 haplotypes on overall survival (OS) and relapse free survival (RFS) were determined by Kaplan-Meier and multivariate Cox regression analysis. The results showed that IL-10 mRNA levels were significantly higher in tumors with the non-ATA haplotype than with the ATA haplotype (P = 0.004). Patients with the non-ATA haplotype had shorter OS and RFS periods than did patients with the ATA haplotype. This may be associated with the observation that the number of tumor-infiltrating lymphocytes was decreased in the tumors with higher levels of IL-10. Consistently, T cells from the peripheral blood of the patients with non-ATA haplotype were more susceptible to apoptosis and less cytotoxic to tumor cells, compared to those from the patients with ATA haplotype. The results suggest that IL-10 can promote tumor malignancy via promoting T cell apoptosis and tumor cell survival, and IL-10 haplotype evaluated by PCR-RFLP or direct sequencing may be used to predict survival and relapse in resected NSCLC, helping clinicians to make appropriate decisions on treatment of the patients.

AB - IL-10 is associated with tumor malignancy via immune escape. We hypothesized that IL-10 haplotypes categorized by IL-10 promoter polymorphisms at -1082A>G, -819C>T, and -592C>A might influence IL-10 expression and give rise to non-small cell lung cancer (NSCLC) patients with poor outcomes and relapse. We collected adjacent normal tissues from 385 NSCLC patients to determine IL-10 haplotypes by direct sequencing and polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Of the 385 tumors, 241 were available to evaluate IL-10 mRNA expression levels by real-time RT-PCR. The influence of IL-10 haplotypes on overall survival (OS) and relapse free survival (RFS) were determined by Kaplan-Meier and multivariate Cox regression analysis. The results showed that IL-10 mRNA levels were significantly higher in tumors with the non-ATA haplotype than with the ATA haplotype (P = 0.004). Patients with the non-ATA haplotype had shorter OS and RFS periods than did patients with the ATA haplotype. This may be associated with the observation that the number of tumor-infiltrating lymphocytes was decreased in the tumors with higher levels of IL-10. Consistently, T cells from the peripheral blood of the patients with non-ATA haplotype were more susceptible to apoptosis and less cytotoxic to tumor cells, compared to those from the patients with ATA haplotype. The results suggest that IL-10 can promote tumor malignancy via promoting T cell apoptosis and tumor cell survival, and IL-10 haplotype evaluated by PCR-RFLP or direct sequencing may be used to predict survival and relapse in resected NSCLC, helping clinicians to make appropriate decisions on treatment of the patients.

UR - http://www.scopus.com/inward/record.url?scp=84864410008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864410008&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0039525

DO - 10.1371/journal.pone.0039525

M3 - Article

C2 - 22848356

AN - SCOPUS:84864410008

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e39525

ER -